Precision oncology company Guardant Health Inc (Nasdaq:GH) said on Wednesday that it has partnered with pharmaceutical company Boehringer Ingelheim to develop a companion diagnostic for zongertinib, an investigational drug for non-small cell lung cancer (NSCLC).
The Guardant360 CDx liquid biopsy will identify NSCLC patients with HER2 mutations who may benefit from zongertinib treatment.
This collaboration aims to streamline patient selection and improve treatment outcomes for patients with advanced lung cancer.
Vivesto strengthens Cantrixil programme with positive preclinical data
Thor Medical signs supply deal with AdvanCell
Abilita and Orion partner on antibody therapeutics for oncology and pain
Breckenridge Pharmaceutical launches FDA approved methadone injection
Pharus Diagnostics unveils liquid biopsy test for early pancreatic cancer detection
Guardant Health and Boehringer Ingelheim partner on lung cancer diagnostic
Mendus reports positive topline data from ovarian cancer trial
Fosun International receives Outstanding ESG Award
Samsung Biologics invests in Generate:Biomedicines
SK Biopharmaceuticals agrees research collaboration with ProEn Therapeutics